


Inflammatory bowel disease and the kidney – causes and consequences

Milena Nikolova Atanas Kundurdjiev Clinic of Nephrology, University Hospital St. Iv. Rilski Medical University-Sofia, Bulgaria




Inflammatory bowel disease



- Inflammatory bowel disease (IBD): chronic inflammatory disease of the gastrointestinal tract.
- Crohn disease (CD) and ulcerative colitis (UC).
- Occurs in genetically susceptible individuals after an exaggerated immune response to a normal stimulus, such as food and intestinal flora.
- Extraintestinal manifestations in 6-46%:
 - Skin,
 - Joints,
 - Eyes,
 - Kidneys 4-23%.




IBD – extraintestinal manifestations



- Systemic reactive manifestations arthritis.
- Autoimmune diseases independent of IBD SLE, thyroiditis.
- Deposition of circulating or in situ formation of immune complexes – GN, TIN.
- Secondary to metabolic derangement AKI in dehydration, renal stones, nephrocalcinosis, TIN.
- Secondary to anatomic derangement urinary tract obstruction, fistulae.
- Side effects of treatment TIN, GN, endothelial damage.



Renal involvement in IBD




- Nephrolithisis CaP, CaOx, Urate, crystalization of medications (sulphasalazine).
- UT obstruction stones, adhesions, RPF.
- Urinary tract infections with or without stones/obstruction.
- GN IgA GN, minimal change, FSGS, MPGN, MGN, anti-GBM.
- Amyloidosis (AA).
- TIN: acute TIN toxic or allergic, granulomatous, immune.
- Acute kidney injury / acute renal failure.
- Chronic kidney disease / chronic renal failure.




Nephrolithiasis in IBD




- Uric acid crystalization due to:
 - Low urine pH,
 - Low urine volume (dehydration in diarrhea),
 - Increased UA levels dehydration, inflammation,
 CS treatment.
- Calcium oxalate hypercalciuria + enteric hyperoxaluria:
 - Bile acid malabsorption,
 - Increased mucosal permeability for oxalates in the colon,
 - Decolonization of Oxybacter formigenes (uses OxAc as energy source).
- Calcium phosphate mainly in CHILDREN, hypercalciuria + hyperphosphaturia due to:
 - Hypovitaminosis D (malabsorption) → increased
 PTH → hypercalciemia + hyperphosphaturia.
 - Nephrocalcinosis.
- Crystalization of medications sulphasalazine.








UT obstruction in IBD



- Nephrolithiasis due to migration of the stone
- RPF entrapment of the ureters in fibrous tissue.
- Adhesions and fistula formation.







Glomeprulonephritis in IBD





• IgA GN:


- Common genetic background HLADR1 in IgA GN and HLA DR1/DQw5 in CD (Takemura et al., Forshaw et al.).
- Increased production of dimeric IgA (Peyer's plaques),
- Impaired clearance of IgA.
- Minimal change nephropathy and FSGS often due to treatment, esp. with anti-TNF agents. Anti-TNF agents bind podocytes and induce apoptosis (Ramos-Casals et al.). Anti —TNF agents can cause cell destruction and generation of ANA, DNA, ANCA Ab and subsequent SLE, ANCA-vasculitis, immune complex GN (Charles et al.).
- C3 GN.
- Anti-GBM GN.
- Membranous GN usually associated with treatment (secondary).
- Membranoproliferative GN HCV should be investigated.
- ANCA-associated vasculitis.
- SLF.
- Takemura T, et al. Pediatr Nephrol. 2002 Oct;17(10):863-6.
- Forshaw MJ, et a. Int J Colorectal Dis. 2005 Sep;20(5):463-5.
- Charles PJ, et al. Arthritis Rheum. 2000 Nov;43(11):2383-90.
- Ramos-Casals M, et al. Medicine (Baltimore). 2007 Jul;86(4):242-251.



lgA












Minimal change GN








FSGS











Membranous GN















Amyloidosis in IBD




- Secondary (AA) type chronic persistent inflammation.
- CD is the fourth leading cause of AA amyloidosis worldwide.
- Nephrotic syndrome WITH progressive renal failure +/- cardiac involvement.
- Hemorrhagic diathesis.




Amyloidosis














CTIN









Drug-induced kidney injury in IBD

- Sulphosalazine crystallization inside the tubular lumen.
- 5-ASA and sulphasalazine acute and chronic TIN.
- Azathioprine TIN and urinary tract infections.
- Anti-TNFa granulomatous TIN, minimal change nephropathy, membranous GN, drug-induced SLE/ANCA-positive disease.
- CsA and TAC endothelial damage → AH, thrombotic microangiopathy, constriction of the afferent arteriole and decreased GFR; TIN.
- Acute and chronic renal failure.




Acute kidney injury in IBD



- TIN usually in response to treatment (toxic or allergic), or in dehydration with high uric acid.
- GN in proliferative GN, vasculitis.
- Urinary tract obstruction stones, RPF, intraabdominal adhesions.
- Ischemic CsA/TAC, low renal perfusion pressure.
- Comorbidities.




Chronic kidney disease in IBD



- TIN toxic, allergic, granulomatous, or in dehydration with high uric acid.
- GN GN, vasculitis.
- Urinary tract obstruction stones, RPF, intraabdominal adhesions, UTI.
- Ischemic CsA/TAC, low renal perfusion pressure.
- Amyloidosis.
- Comorbidities.




Our series with kidney changes in IBD



- 37 consecutive patients with IBD:
 - 16 female and 21 male,
 - mean age 47 years,
 - 19 CD and 18 UC,
 - observed for 6 years from January 2017 to January 2023.
- The most prevalent type of renal involvement was:
 - GN in 13 (minimal change GN 6, focal and segmental glomerulosclerosis - 4, IgA GN - 2, membranoproliferative glomerulonephritis - 1), followed by
 - tubulointerstitial nephritis 12,
 - nephrolithiasis 8,
 - diabetic nephropathy 6,
 - renal amyloidosis 4 (the total number is > 37 because several patients had >1 type of renal involvement).




Our series with kidney changes in IBD



- The most common type of renal involvement in our series was <u>GN</u>, but <u>also non-immune changes</u> were observed.
- The presence of erythrocyturia, proteinuria > 500 mg/day and renal failure should prompt the physician to perform renal biopsy in order to distinguish immune from non-immune mediated renal injury in IBD and to undertake timely and adequate treatment.





THANK YOU FOR YOUR ATTENTION!